Search

Motor behaviours, like where to step and which path to walk, rely on gaze shifts to gather visual information necessary to decide the next action. Factors influencing both gaze and walking decisions are poorly understood. Here we had people choose between two paths to determine how a person's belief in their ability to walk across different terrains (i.e., self-efficacy) competed with the expected cost of walking different lengths in deciding how to allocate gaze and the choice of path. When paths differed in both length and terrain, participants directed gaze progressively more to the longer path as self-efficacy about it increased and the difference in rating with the shorter path grew. Participants also chose the higher-rated path more frequently regardless of path length. These results demonstrate that self-efficacy contributes to gaze and walking decisions and suggest that it may play a more dominant role versus energetic cost in both behaviours., Competing Interests: Declarations. Competing interests: The authors declare no competing interests., (© 2024. The Author(s).)

Decisions about where to move occur throughout the day and are essential to life. Different movements may present different challenges and affect the likelihood of achieving a goal. Certain choices may have unintended consequences, some of which may cause harm and bias the decision. Movement decisions rely on a person gathering necessary visual information via shifts in gaze. Here we sought to understand what influences this information-seeking gaze behavior. Participants chose between walking across one of two paths that consisted of terrain images found in either hiking or urban environments. We manipulated the number and type of terrain of each path, which altered the amount of available visual information. We recorded gaze behavior during the approach to the paths and had participants rate the confidence in their ability to walk across each terrain type (i.e., self-efficacy) as though it was real. Participants did not direct gaze more to the path with greater visual information, regardless of how we quantified information. Rather, we show that a person's perception of their motor abilities predicts how they visually explore the environment with their eyes as well as their choice of action. The greater the self-efficacy in walking across one path, the more they directed gaze to it and the more likely they chose to walk across it.

We investigated the bioavailability of the calcium salt (HMB-Ca) and the free acid (HMB-FA) forms of β-hydroxy-β-methylbutyrate (HMB). Sixteen young individuals received the following treatments on three different occasions in a counterbalanced crossover fashion: (1) HMB-FA in clear capsules; (2) HMB-Ca in gelatine capsules; (3) HMB-Ca dissolved in water. All treatments provided 1 g of HMB. Blood samples were taken before and on multiple time points following ingestion. The following parameters were calculated: peak plasma (Cmax), time to peak (Tmax), slope of HMB appearance in blood, area under the curve (AUC), half-life time (t 1/2 ) and relative bioavailability (HMB-Ca in water set as reference). All treatments led to rapid and large increases in plasma HMB. HMB-Ca in capsules and in water showed similar plasma HMB values across time (p = 0.438). HMB-FA resulted in lower concentrations vs. the other treatments (both p < 0.001). AUC (HMB-Ca in capsules: 50,078 ± 10,507; HMB-Ca in water: 47,871 ± 10,783; HMB-FA: 29,130 ± 12,946 µmol L -1  × 720 min), Cmax (HMB-Ca in capsules: 229.2 ± 65.9; HMB-Ca in water: 249.7 ± 49.7; HMB-FA: 139.1 ± 67.2 µmol L -1 ) and relative bioavailability (HMB-Ca in capsules: 104.8 ± 14.9%; HMB-FA: 61.5 ± 17.0%) were lower in HMB-FA vs. HMB-Ca (all p < 0.001). HMB-Ca in water resulted in the fastest Tmax (43 ± 22 min) compared to HMB-Ca in capsules (79 ± 40 min) and HMB-FA (78 ± 21 min) (all p < 0.05), while t 1/2 was similar between treatments. To conclude, HMB-Ca exhibited superior bioavailability compared to HMB-FA, with HMB-Ca in water showing faster absorption. Elimination kinetics were similar across all forms, suggesting that the pharmaceutical form of HMB affects the absorption rates, but not its distribution or elimination., (© 2024. The Author(s).)